Voyager Therapeutics to Host R&D Day on November 16, 2017
November 12 2017 - 6:00PM
Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene
therapy company focused on developing life-changing treatments for
severe neurological diseases, announced today it will host an
R&D Day program and webcast for the investment community
in New York City on November 16, 2017 from 2:00-5:00
p.m. EST. Members of Voyager Therapeutics’ senior management team,
along with a guest movement disorder specialist speaker, will
provide an overview of the following programs and initiatives:
- VY-AADC for advanced Parkinson’s disease
- Novel adeno-associated virus (AAV) capsids and delivery
optimization efforts
- ALS, Huntington’s disease, Friedreich’s ataxia, anti-Tau
antibody and severe chronic pain programs
Planned presenters include senior executives from Voyager
Therapeutics’ scientific, clinical and management team, as well as
a featured movement disorder specialist guest speaker:
- Steven Paul, M.D., president and chief executive officer
- Jane Henderson, chief financial officer and senior vice
president of corporate development
- Bernard Ravina, M.D., M.S., chief medical officer
- Dinah Sah, Ph.D., chief scientific officer
- Matthew Ottmer, chief operating officer
- Luis Maranga, Ph.D., chief technical operations officer
- Andrew Siderowf, M.D., M.S., chief of the movement disorders
division, University of Pennsylvania, Department of Neurology
Live-streaming webcast can be accessed through the Investors
& Media sections of the Voyager’s website at
www.voyagertherapeutics.com. The webcast will be archived for 30
days after the live event concludes.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene
therapy company focused on developing life-changing treatments for
severe neurological diseases. Voyager is committed to advancing the
field of AAV gene therapy through innovation and investment in
vector engineering and optimization, manufacturing and dosing and
delivery techniques. The company’s pipeline focuses on severe
neurological diseases in need of effective new therapies, including
advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s
disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s
disease and severe, chronic pain. Voyager has broad strategic
collaborations with Sanofi Genzyme, the specialty care global
business unit of Sanofi, and the University of Massachusetts
Medical School. Founded by scientific and clinical leaders in
the fields of AAV gene therapy, expressed RNA interference and
neuroscience, Voyager Therapeutics is headquartered in Cambridge,
Massachusetts. For more information, please visit
www.voyagertherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. The use of words such as “may,” “might,” “will,”
“should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,”
“undoubtedly,” “project,” “intend,” “future,” “potential,” or
“continue,” and other similar expressions are intended to identify
forward-looking statements. For example, all statements
Voyager makes regarding the initiation, timing, progress and
reporting of results of its preclinical programs and clinical
trials and its research and development programs, its ability to
advance its AAV-based gene therapies into, and successfully
initiate, enroll and complete, clinical trials, the potential
clinical utility of its product candidates, its ability to continue
to develop its product engine, its ability to add new programs to
its pipeline, its ability to enter into new partnerships or
collaborations, its expected cash, cash equivalents and marketable
debt securities at the end of a fiscal year and anticipation for
how long expected cash, cash equivalents and marketable debt
securities will last, and the timing or likelihood of its
regulatory filings and approvals, are forward looking. All
forward-looking statements are based on estimates and assumptions
by Voyager’s management that, although Voyager believes to be
reasonable, are inherently uncertain. All forward-looking
statements are subject to risks and uncertainties that may cause
actual results to differ materially from those that Voyager
expected. Such risks and uncertainties include, among others,
those related to the initiation and conduct of preclinical studies
and clinical trials, the availability of data from clinical trials
and the expectations for regulatory submissions and approvals; the
continued development of the product engine; Voyager’s scientific
approach and general development progress; the availability or
commercial potential of Voyager’s product candidates; the
sufficiency of cash resources; and need for additional financing.
These statements are also subject to a number of material risks and
uncertainties that are described in Voyager’s most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, as updated by its subsequent filings with the
Securities and Exchange Commission. Any forward-looking
statement speaks only as of the date on which it was made.
Voyager undertakes no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law.
Investor Relations: Matt
OsborneVice President of Investor Relations & Corporate
Communications857-259-5353mosborne@vygr.com
Media:
Katie EnglemanPure Communications,
Inc.910-509-3977Katie@purecommunicationsinc.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Apr 2023 to Apr 2024